Atai Life Sciences N.V. (ATAI)
USD 1.18
(-10.61%)
USD 1.18
(-10.61%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -84.11 Million | -104.46 Million | -63.24 Million | -20.76 Million | -7.84 Million |
| Net Income | -40.22 Million | -157.41 Million | -174.24 Million | -178.62 Million | -24.38 Million |
| Depreciation & Amortization | 319 Thousand | 168 Thousand | 47 Thousand | 24 Thousand | 6000.00 |
| Deferred income taxes | -124 Thousand | 5.07 Million | 39.13 Million | 56.34 Million | 7.53 Million |
| Stock-based compensation | 32.98 Million | 42.37 Million | 63.36 Million | 67.15 Million | 57 Thousand |
| Change in working capital | 7.46 Million | -3.33 Million | -7.6 Million | 4.45 Million | -126 Thousand |
| Other non-cash items | -84.54 Million | 8.66 Million | 16.05 Million | 29.88 Million | 9.06 Million |
| Investing Cash Flow | -53.29 Million | -86.84 Million | -81.27 Million | -28.27 Million | -9.03 Million |
| Investments in PPE | -590 Thousand | -1.02 Million | -1.12 Million | -59 Thousand | -19 Thousand |
| Acquisitions | -443 Thousand | - | -52.93 Million | -2.08 Million | -456 Thousand |
| Investment purchases | -185.26 Million | -309.65 Million | -23.65 Million | -23.92 Million | -11.55 Million |
| Sales/Maturities of investments | 139.46 Million | 226.83 Million | -955 Thousand | - | 10.31 Million |
| Other Investing Activities | -6.46 Million | -3 Million | -2.59 Million | -2.2 Million | -7.31 Million |
| Financing Cash Flow | -8.35 Million | 20.78 Million | 409.86 Million | 113.05 Million | 40.38 Million |
| Debt repayment | -8.58 Million | -13.25 Million | -1.58 Million | -32.5 Million | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 225 Thousand | 4.63 Million | 409.88 Million | 82.43 Million | 42.68 Million |
| Other Financing Activities | -8.35 Million | 29.4 Million | 1.56 Million | 63.11 Million | -2.29 Million |
| Accounts receivables | -2.01 Million | - | - | - | - |
| Accounts payables | 2.13 Million | -3.03 Million | 2.3 Million | 1.7 Million | 249 Thousand |
| Inventory | 2.01 Million | - | - | - | - |
| Other working capital | 5.33 Million | -301 Thousand | -9.9 Million | 2.74 Million | -375 Thousand |
| Cash at beginning of period | 190.61 Million | 362.26 Million | 97.24 Million | 30.06 Million | 6.92 Million |
| Cash at end of period | 45.03 Million | 190.61 Million | 362.26 Million | 97.24 Million | 30.06 Million |
| Capital Expenditure | -590 Thousand | -1.02 Million | -1.12 Million | -59 Thousand | -19 Thousand |
| Effect of forex changes on cash | 189 Thousand | -1.12 Million | -320 Thousand | 3.16 Million | -372 Thousand |
| Net cash flow / Change in cash | -145.57 Million | -171.65 Million | 265.02 Million | 67.18 Million | 23.14 Million |
| Free Cash Flow | -84.7 Million | -105.49 Million | -64.37 Million | -20.82 Million | -7.86 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -57.31 Million | -26.71 Million | -18.29 Million | -40.22 Million | 43.37 Million | -33.77 Million |
| Depreciation & Amortization | 82 Thousand | 83 Thousand | 101 Thousand | 319 Thousand | 74 Thousand | 79 Thousand |
| Deferred income taxes | - | - | -8.49 Million | -124 Thousand | -70.88 Million | 1.4 Million |
| Stock-based compensation | 6.28 Million | 5.76 Million | 7.3 Million | 32.98 Million | 8.25 Million | 8.76 Million |
| Change in working capital | 2.88 Million | -5.01 Million | 2.56 Million | 7.46 Million | 341 Thousand | 831 Thousand |
| Other non-cash items | 38.45 Million | 9.97 Million | -4.28 Million | -84.54 Million | 416 Thousand | 81 Thousand |
| Investing Cash Flow | 16.18 Million | 11.47 Million | -189.28 Thousand | -53.29 Million | -46.48 Million | -22 Million |
| Investments in PPE | 19.98 | -5000.00 | -10.03 Thousand | -590 Thousand | -2000.00 | -128 Thousand |
| Acquisitions | - | - | 37 Thousand | -443 Thousand | 2000.00 | 157 Thousand |
| Investment purchases | -65.17 Million | -31.36 Million | -5.31 Million | -185.26 Million | -138.15 Million | -39.61 Million |
| Sales/Maturities of investments | 84.26 Million | 43.84 Million | 7 Million | 139.46 Million | 93.64 Million | 17.74 Million |
| Other Investing Activities | -2.89 Million | -1 Million | -1.9 Million | -6.46 Million | -1.97 Million | -157 Thousand |
| Financing Cash Flow | 324.69 Thousand | - | -8.46 Million | -8.35 Million | -47.68 | -100 Thousand |
| Debt repayment | - | - | -8.43 Million | -8.58 Million | -44.98 | -100.71 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 324.69 Thousand | - | 16.42 Thousand | 225 Thousand | -92.67 | 1478.22 |
| Other Financing Activities | 326 Thousand | - | -8.46 Million | -8.35 Million | - | -100 Thousand |
| Accounts receivables | - | -1 Million | -2.01 Million | -2.01 Million | - | - |
| Accounts payables | -18.94 Thousand | -742 Thousand | -990.08 Thousand | 2.13 Million | 1.69 Million | -1.07 Million |
| Inventory | - | - | - | 2.01 Million | - | - |
| Other working capital | 2.9 Million | -4.27 Million | 3.55 Million | 5.33 Million | -1.35 Million | 1.9 Million |
| Cash at beginning of period | 23.86 Million | 45.03 Million | 76.49 Million | 190.61 Million | 141.09 Million | 185.88 Million |
| Cash at end of period | 34.33 Million | 23.86 Million | 45.03 Million | 45.03 Million | 76.49 Million | 141.09 Million |
| Capital Expenditure | 19.98 | -5000.00 | -10.03 Thousand | -590 Thousand | -2000.00 | -128 Thousand |
| Effect of forex changes on cash | 66 Thousand | -64 Thousand | -212 Thousand | 189 Thousand | 318 Thousand | -76 Thousand |
| Net cash flow / Change in cash | 10.46 Million | -21.16 Million | -31.45 Million | -145.57 Million | -64.59 Million | -44.79 Million |
| Free Cash Flow | -16.07 Million | -22.57 Million | -21.11 Million | -84.7 Million | -18.43 Million | -22.74 Million |
AVROIND
VZIO
1961
GOYALALUM
8005
CGCLF